Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 9/20 | 0.41 |
| ▸ | XIAP | P98170 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16116404 | 1.00 | CXCR3 (0.41) | CXCR3XIAPKDM4EALDH1A1CYP1A2 | |
| SCHEMBL16116407 | 1.00 | CXCR3 (0.41) | CXCR3XIAPKDM4EALDH1A1CYP1A2 | |
| SCHEMBL17600357 | 0.96 | XIAP (0.40) | CXCR3XIAPKDM4EALDH1A1CYP1A2 | |
| SCHEMBL17600359 | 0.96 | XIAP (0.40) | CXCR3XIAPKDM4EALDH1A1CYP1A2 | |
| SCHEMBL17600355 | 0.96 | XIAP (0.40) | CXCR3XIAPKDM4EALDH1A1CYP1A2 | |
| SCHEMBL17600510 | 0.96 | XIAP (0.40) | CXCR3XIAPKDM4EALDH1A1CYP1A2 | |
| SCHEMBL17600464 | 0.94 | CXCR3 (0.42) | CXCR3XIAPKDM4EALDH1A1CYP1A2 | |
| SCHEMBL16115755 | 0.94 | CXCR3 (0.42) | CXCR3XIAPKDM4EALDH1A1CYP1A2 | |
| SCHEMBL17600425 | 0.92 | XIAP (0.42) | CXCR3XIAP | |
| SCHEMBL17600424 | 0.92 | XIAP (0.42) | CXCR3XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329324-B2 | Indoline compounds as granzyme B inhibitors | viDA Therapeutics (CA) | 2019-06-25 | — | — | US | disclosed |
| US-20180057528-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2018-03-01 | — | — | US | disclosed |
| US-9605021-B2 | Indoline compounds as granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2017-03-28 | — | — | US | disclosed |
| US-20160083422-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057528-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, PRF1, CTSB | CXCR3 151/4885XIAP 107/4885KDM4E 3437/4885 |
| US-10329324-B2 | Indoline compounds as granzyme B inhibitors | GZMB, PRF1, CTSB | CXCR3 151/4885XIAP 107/4885KDM4E 3437/4885 |
| US-20160083422-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, PRF1, CTSB | CXCR3 151/4885XIAP 107/4885KDM4E 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.